Despite the controversies on their brain specificity, S100B and NSE have been investigated in different brain diseases as peripheral markers of therapeutic interventions, as well as of neurological and neuropsychological outcome [14,16,22-24]. This evidence concerns the gene ENO2 and brain disorder.